Phase Genomics Receives $1.5 Million Grant to Advance Microbiome Discovery

Share Article

The Phase II SBIR Grant from the National Institute of Allergy and Infectious Diseases funds development of an affordable sequencing test for metagenomic samples

“Phase Genomics’ Hi-C based proximity ligation technology enables a whole new level of discovery in the microbiome realm,” said Dr. Ivan Liachko, CEO and Co-founder of Phase Genomics.

Phase Genomics (http://www.phasegenomics.com), the leader in Hi-C proximity ligation based genomic solutions, announced today the receipt of a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID). The two-year grant will be utilized to develop an affordable, high-throughput Hi-C kit and computational analysis platform to accelerate microbiome research and discovery.

The human body and the environment are dominated by poorly understood communities of microorganisms, which have profound effects on human health, agricultural production, and diverse industrial processes. Yet, little is known about the potentially trillions of microorganisms which live in, on, and around humans opening vast opportunities in research and development.

“Phase Genomics’ Hi-C based proximity ligation technology enables a whole new level of discovery in the microbiome realm,” said Dr. Ivan Liachko, CEO and Co-founder of Phase Genomics, “It lets us assemble whole genomes from microbiome samples with no prior information. It solves the massive problem of understanding the genetics of organisms that cannot be cultured, which is the lion’s share of microbes living in the environment. Our Hi-C kit is compatible with fecal, clinical, and environmental samples, and even air pollutants. The technology generates numerous novel genomes per sample, providing valuable insights and enabling otherwise inaccessible discoveries that will save time, money and hopefully lives.”

Metagenomic sequencing, the process of discovering and cataloging microorganisms within microbiome communities, has already proven itself to be highly useful in many areas, including human disease and enhancing ecologically friendly agricultural practices. Adding proximity ligation data drastically improves the insights gained from each sample, but involves a relatively novel, low-throughput process. The grant is aimed at overcoming the current throughput limitations of proximity ligation, making this highly innovative technology cheaper and more accessible to a wide range of researchers.

Phase Genomics’ previously received funding from the NIAID in form of a Phase I SBIR as well as investment from WRF Capital and Congruent Ventures.

Media Inquiries: eric(at)phasegenomics.com

ABOUT PHASE GENOMICS – Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software. Based in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company’s mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Eric Schudiske
s2s Public Relations
+1 (206) 310-3597
Email >
@PhaseGenomics
since: 10/2014
Follow >
Phase Genomics

Visit website